



Published in final edited form as:

*J Perinatol.* 2020 July ; 40(7): 1100–1108. doi:10.1038/s41372-020-0605-5.

## Evaluation of the economic impact of modified screening criteria for retinopathy of prematurity from the Postnatal Growth and ROP (G-ROP) Study

John A. F. Zupancic, MD ScD<sup>1,2</sup>, Gui-shuang Ying, PhD<sup>3,4</sup>, Alejandra de Alba Campomanes, MD MPH<sup>5</sup>, Lauren A. Tomlinson, BS<sup>3,4</sup>, Gil Binenbaum, MD MSCE<sup>3,4</sup> G-ROP Study Group

<sup>1</sup>Division of Newborn Medicine, Harvard Medical School, Boston, Massachusetts, USA

<sup>2</sup>Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

<sup>3</sup>Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

<sup>4</sup>The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

<sup>5</sup>University of California, San Francisco, California, USA

### Abstract

**Importance**—The Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study showed that addition of postnatal weight gain to birth weight and gestational age detects similar numbers of infants with ROP, but requires examination of fewer infants.

**Objective**—To determine the incremental cost-effectiveness of screening with G-ROP compared to Conventional Screening.

**Design, Setting and Participants**—We built a microsimulation model of a one-year US birth cohort <32 weeks gestation, using data from the G-ROP study. We obtained resource utilization estimates from the G-ROP dataset and from secondary sources, and test characteristics from the G-ROP cohort.

**Results**—Among 78,281 infants nationally, screening with G-ROP detected approximately 25 additional infants with Type 1 ROP. This was accomplished with 36,233 fewer examinations, in 14,073 fewer infants, with annual cost savings of approximately \$2,931,980 USD through hospital discharge.

**Conclusions**—Screening with G-ROP reduced costs while increasing the detection of ROP compared to current screening guidelines.

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence and reprint requests: John A. F. Zupancic, MD, ScD, Department of Neonatology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rose Building Room 318, Boston, MA 02215, TEL: (617) 667-3276, FAX: (617) 667-7040, [jzupanci@bidmc.harvard.edu](mailto:jzupanci@bidmc.harvard.edu).

## Keywords

Infant; newborn; retinopathy of prematurity; economic evaluation

---

## INTRODUCTION

Retinopathy of prematurity (ROP) is one of the leading causes of severe childhood visual impairment in middle- and high-income countries. Infants who develop a significant severity of disease known as Type 1 ROP have a more than 50% likelihood of unfavorable visual outcome (defined functionally as visual acuity four standard deviations below the mean, or structurally as posterior retinal fold or detachment involving the macula) (1). However, with treatment, this probability can be reduced substantially (2, 3).

ROP is diagnosed almost exclusively in infants who are born at gestational age below 32 weeks or birth weight below 1,500 grams, but does not develop for several weeks after birth. Serial retinal examinations with indirect ophthalmoscopy can reliably detect Type 1 disease in high-risk infants in time for intervention to take place. Current consensus recommendations by professional societies recommend screening of all infants born at less than 1,501 grams, or less than or equal to 30 weeks, or those between 1,500 and 2,000 grams with hypotension or substantial oxygen exposure (4).

Although the currently recommended guidelines have high sensitivity for detection of ROP, their specificity is low, and the great majority of screened infants never develop ROP that requires intervention. Over the last 15 years, several predictive models have suggested that the addition of suboptimal postnatal growth to birth weight and gestational age maintained sensitivity of screening criteria while substantially improving specificity, but these studies were based on relatively small cohorts (5–10). Recently, the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study examined a cohort of 7,483 preterm infants to develop a predictive model that included such modified screening criteria, with resulting sensitivity of 100% and specificity of 32%, both superior to traditional birthweight and gestational age screening alone in the study cohort (11). Given the substantial reduction of the number of infants requiring serial ophthalmological examinations using these criteria, we undertook a study to determine the economic implications of adopting such a screening strategy.

## METHODS

### Study Design and Model Specification

We developed a decision analytic microsimulation model to evaluate the proposed G-ROP revision to current screening criteria for ROP, using TreeAge Pro Suite software (TreeAge Software Inc 2017, Williamstown, MA). The model, presented in schematic form in Figure 1, generated estimates of resource utilization and outcomes associated with ROP for a hypothetical one-year national birth cohort under various assumptions of the criteria employed for screening.

We compared two approaches to screening. The first comparator (Conventional Screening, CS) was based on the current guideline of the American Academy of Ophthalmology and the American Academy of Pediatrics, which recommend screening of infants with birth weight 1,500 grams or less, or gestational age at birth 30 weeks or less (4). The second comparator (G-ROP) incorporated the G-ROP criteria, in which infants are screened if they meet any one of the following criteria: gestational age at birth less than 28 weeks; or birth weight less than 1051 grams; or weight gain of less than 120 g, 180 g, or 170 g during ages 10 to 19, 20 to 29, or 30 to 39 days, respectively; or hydrocephalus (11). Of note, a subjective third criterion is presently used clinically, in which infants with birth weight between 1,500 and 2,000 grams may receive retinal examinations if they have had an unstable clinical course in the judgment of the treating neonatologist (4). For a valid comparison to be made among the two screening approaches, a subjective criterion also could be added to the G-ROP criteria. However, because this criterion is subjective and nonspecific, it was not considered as part of either the current CS guidelines or the G-ROP criteria in this analysis.

The model was formulated in two versions. In the first phase (“Discharge”), we sought to minimize model assumptions by limiting model efficacy inputs to those available in the G-ROP database. This version analyzed only short-term outcomes through hospital discharge, and included screening and acute treatment costs, and the number of cases of treatable ROP detected. In the second phase (“Lifetime”), we employed literature sources to extend these results to the lifetime horizon, in order to include severe visual impairment and quality of life, as well as broader societal estimates of costs.

### Description of Primary Analysis (Discharge)

**Framing**—The planned main outcome for the primary analysis was the incremental cost (  $C$  ) incurred by a proposed G-ROP Screening strategy relative to a Conventional Screening strategy, divided by its incremental effectiveness (  $E$  ). The resulting incremental cost-effectiveness ratio (  $C / E$  ) represented the cost-effectiveness of G-ROP screening, expressed in terms of the additional cost per additional infant with Type 1 ROP detected.

Secondary outcomes included the number of infants screened and the number of examinations performed annually in the United States, as well as the annual number of false positive screening results (those infants without Type 1 ROP who were selected for examination by each model) and the number of false negative screening results (those infants with Type 1 ROP who were missed by each model).

The primary analysis was performed from the perspective of a third-party payer, in which only direct medical costs were included, and with a time horizon to first discharge home from hospital.

Institutional review board approval was obtained and a waiver of consent was granted for the collection of deidentified data in the original study cohort at all participating hospitals.

**Model Inputs: Effectiveness**—Inputs for effectiveness are provided in Table 1. Effectiveness in our model was expressed as the proportion of cases of Type 1 ROP detected,

which were defined as those diagnosed in the large, multi-center G-ROP cohort as meeting the Early Treatment of Retinopathy of Prematurity (ETROP) Study Type 1 ROP criteria (2). The gestational-age-specific probability of developing Type 1 ROP was estimated directly from its incidence in the G-ROP study database (12).

In the G-ROP clinical study, the screening criteria had sensitivity 100% (95% CI, 99.2%–100%) and specificity 32.3% (95% CI, 31.2%–33.4%) for the detection of Type 1 ROP. In the same population, Conventional Screening criteria had sensitivity 99.4% (95% CI, 98.1%–99.8%) and specificity 11.8% (95% CI, 11.0%–12.6%) (11).

**Model Inputs: Resource Use and Costs**—Estimates for resource utilization and costs are provided in Table 1. Prior to the start of the G-ROP Study, resource utilization data were collected and assessed on a sample of 100 infants undergoing ROP examinations at three hospitals in Seattle and Philadelphia. No changes in non-ROP-related resource utilization were associated with ROP examinations, including changes in respiratory support, nutrition, radiograph usage, laboratory tests, and non-ophthalmological surgeries and procedures (data not shown). Therefore, we proceeded under the assumption that the only differences in resource utilization prior to discharge for ROP evaluations were those related to screening or treatment of ROP. We estimated the frequency of ophthalmological examinations per patient from G-ROP case report forms, which collected data on all eye examinations.

Because neither professional nor institutional billing reliably reflect the personnel effort, we estimated professional time input in an observational time and motion study of individuals involved in care of infants undergoing ROP diagnostic examinations (13). Ophthalmologists, neonatal nurses, ophthalmic technicians, and ROP coordinators were timed using digital timers and standardized data collection forms for work completed at four neonatal intensive care units and two outpatient ophthalmology clinics in Philadelphia and San Francisco between February and December 2014. Primary outcomes were the overall and subtask times per infant. Seven pediatric ophthalmologists and eight ophthalmic technicians were timed performing 303 inpatient and 37 outpatient ROP exams (Table 1).

Hourly time costs of physicians, registered nurses, and administrative support staff for examinations were calculated from the Doximity physician salary survey and U.S. government data, respectively (14, 15). A 30% fringe rate was added to these values to account for institutional overhead costs. Because infants were assumed to be resident in the NICU and therefore subject to bundled institutional reimbursement, a separate institutional technical fee for these examinations was not included. Costs for laser photocoagulation procedures and retinal procedures were derived from previously published micro-costed estimates by our group (16).

Total costs were calculated as the product of the resources used and the unit prices associated with those resources. Although incurred between 2006 and 2012, all costs are expressed in this report in 2017 US dollars (USD). Where necessary, we converted costs from other dates using the Personal Consumption Expenditure Health price deflator from the Center for Medicare and Medicaid Services (17, 18). Because the time horizon for the

primary analysis was less than one year, discounting was not undertaken in the primary analysis.

**Model Inputs: Population Characteristics**—We used data from the U.S. National Center for Health Statistics to assign the frequency of birth at each week of gestational age (eTable 1), and the distribution of birth weights within each week of gestational age (eTables 2a – 2k) (19).

**Uncertainty and Heterogeneity**—In order to reflect the heterogeneity of the population to whom the results will be applied, we conducted a computer microsimulation of a one-year United States birth cohort, in which each infant was assigned a birthweight and gestational age based on empirical data for infants between 22 and 32 weeks from the 2017 US census (the most recent year available) (19), followed by a risk of ROP based on these characteristics. Infants then proceeded through the model, one infant at a time, and were screened and accrued costs and outcomes according to their baseline characteristics and the probabilities of detection encountered in the model. At the end of the cohort, the average cost and effectiveness across all infants, and the incremental cost-effectiveness ratio, was calculated.

We repeated this simulation with 1000 cohorts, corresponding to 1000 years. Sampling uncertainty was assessed for sensitivity, specificity, number of examinations, and professional time by entering these into the model as distributions, the details of which are provided in Table 1. At the start of each cohort, the model drew randomly from each of these distributions, and that estimate was employed for all infants in that year.

We also performed deterministic sensitivity analysis, in which a specific input to the model was changed through the upper and lower range of plausible values, and the entire simulation re-run using that value, in order to determine the impact on the resulting costs and effectiveness. Best-case and worst-case scenarios were implemented by varying multiple inputs simultaneously.

### **Description of Secondary Analysis (Lifetime)**

The Lifetime analysis sought to optimize generalizability of the results and the ability to compare them to other health care programs, and thus differed in several ways from the primary model. First, it employed a societal perspective, in which all costs were considered, including family out-of-pocket expenses, productivity (wage) losses to both the patient in later life and to the infant's family, and educational and other expenditures by non-medical agents. These costs were considered over a lifetime time horizon rather than to first discharge home. Visual outcomes were converted to utilities, or the individuals' preferences for living with either normal or poor visual outcomes, and the results expressed as quality adjusted life years, defined as the utility multiplied by the average life expectancy in a given state of visual function. Costs were discounted at 3% per annum, and this rate was varied in sensitivity analysis (20). Other aspects of the model were similar to those in the primary analysis.

## RESULTS

Each microsimulation run included a one-year cohort of 78,281 infants (19). Screening with G-ROP, compared with Conventional Screening (CS), detected approximately 25 additional infants with Type 1 ROP (Table 2). This improved detection was accomplished despite 36,233 fewer examinations being performed, in 14,073 fewer infants, and at an annual cost savings of approximately 2,931,980 USD in the short run and 12,873,157 USD in the long run. These savings correspond to 9.5% and 2.6%, respectively, of the total annual relevant ROP-related expenditure. The lower costs and higher effectiveness of G-ROP screening indicate that it is a “dominant” option, compared to Conventional Screening (Table 3).

Results for the probabilistic sensitivity analysis, reflecting sampling uncertainty for all the distributional inputs listed in Table 1, are shown in Figure 2. Each dot on this cost-effectiveness scatterplot represents the incremental cost and effectiveness of one of the 1,000 replications of our one-year cohort of patients. Of these, 97.2% are in the right lower quadrant, with lower costs and higher effectiveness, indicating a 97.2% probability that G-ROP screening is a dominant option. A similar result is depicted in the Cost-Effectiveness Acceptability Curve in eFigure 1, which plots the proportion of replications that would be considered “cost-effective” for a decision maker who had the willingness-to-pay (WTP) for one additional case of ROP detected listed on the horizontal axis (21). In this plot, G-ROP is a preferred option even at a WTP of 0, and rapidly approaches 100% probability of desirability at higher WTP.

Findings from deterministic sensitivity analyses are presented in eTable 3. Despite varying the cost inputs over a very broad range of 70% to 130% of the baseline value, both individually and as a group, there was minimal change in the proportion of replications in which G-ROP Screening was a dominant option. Similarly, we substituted the progression to unfavorable structural outcome seen with cryotherapy in the original CRYO-ROP trial (22) for the superior efficacy in the intervention arm of the ET-ROP trial (2), as well as for a hypothetical lower progression than ET-ROP, neither of which resulted in a probability of dominance below 90%. Finally, we varied all of the above inputs simultaneously, in best and worst-case scenarios, for which the probabilities of dominance were 97.2% and 90.8%, respectively.

The Lifetime model showed similar results with a lifetime time horizon and societal perspective, with G-ROP simultaneously yielding lower costs and more quality adjusted life years than the conventional screening strategy, at a very high probability of 98.8% in probabilistic sensitivity analysis (eTable 4). The direction of this result was again robust to changes in input assumptions (eTable 3).

## DISCUSSION

In this microsimulation cost-effectiveness study of a US birth cohort born between 22 and 32 weeks gestational age, implementing screening criteria using the G-ROP model was an economically dominant strategy. Identifying infants as eligible for ophthalmological screening for ROP using the G-ROP screening criteria, which incorporate postnatal weight

gain and hydrocephalus in addition to gestational age and birth weight criteria, increased the number of infants identified with Type 1 ROP while simultaneously reducing the number of examinations and decreasing costs. The results were robust to adjustments in the underlying assumptions about efficacy and costs.

Although several modeling analyses of the economic implications of ROP management have been reported, these compared either interventions (such as treatment at an earlier stage of retinal pathology), telemedicine screening devices, or combinations of screening and intervention (16, 23–27). To our knowledge, no studies have specifically compared the cost-effectiveness of one of the newer, weight-velocity based screening algorithms with conventional screening.

This study has several notable strengths. First, we incorporate the results of the development of a revised screening approach in a large dataset. The analysis considers both the heterogeneity of the population of eligible infants, by assigning birth weight, gestational age and gestational-age-specific ROP incidence to individual infants, as well as sampling uncertainty related to important parameters such as sensitivity and specificity, using distributions that reflect the variance in the studies that generated the estimates. Moreover, the analyses were designed to simultaneously address the cost-effectiveness of G-ROP compared to conventional screening, as well as the national implications in terms of numbers of infants exposed to screening, and the numbers screened who have little to no likelihood of developing serious ROP. Such explicit national estimates of the burden of screening will hopefully be of use in policy discussions of recommendations for screening strategies.

Certain limitations must be noted. First, although the initial G-ROP dataset included a large sample of infants, the approach has not to date been independently validated in a separate clinical sample, which is necessary prior to clinical adoption. There is a risk that overfitting to the current data set may have resulted in an over-estimation of sensitivity and specificity, although the large development cohort minimizes this possibility. The economic model incorporates the sampling uncertainty in both of these test characteristics, but it does not consider the possibility of systematic bias in that distribution. Validation in a prospectively collected U.S. dataset is underway now, and the economic model will be re-run in this sample when available. Even with this revalidation, the generalizability to developing health care systems will remain uncertain until retested in those settings, where the characteristics of infants developing severe ROP differs considerably, and the G-ROP criteria may not be reliable. Second, in the absence of reliable national estimates, we applied the gestational age-specific incidence of ROP from the G-ROP study to the national cohort in our model. Changes in incidence will not alter the sensitivity or specificity of the model, but they could potentially alter the economic implications. Third, while in the simulation the use of the G-ROP criteria increased detection of Type 1 ROP by 25 cases per year compared to conventional BW and GA criteria, these cases are likely being captured in practice by use of the subjective third criterion of an unstable clinical course in the judgment of the neonatologist, which was not included in the model due to the infeasibility of quantification. In contrast, the G-ROP criteria had 100% sensitivity without the need for a subjective criterion. Therefore, even if such a criterion were to be added for both

strategies and consequently sensitivity increased to 100% for conventional screening, the study conclusions would not change, as the G-ROP criteria would still demonstrate “weak dominance,” in which costs are lower but outcomes the same. Finally, we note that there are undoubtedly missed appointments and delayed examinations. These are included in the numbers of examinations estimated in the retrospective G-ROP dataset and should be similar in both groups, and variations are included as these were entered into the model as distributions. If the results are applied to a population that has a very different rate of compliance, however, the impact of screening might differ as well.

## CONCLUSIONS

The G-ROP modified screening criteria are a dominant, economically desirable strategy when compared to the conventional screening. If validated and subsequently applied in clinical practice, their use would improve detection of treatment-requiring ROP while simultaneously greatly reducing the number of infants receiving retinal examinations and the number of examinations being performed, with resultant cost savings.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

**Funding/Support:** This study was supported by the National Institutes of Health grant R01EY021137, and the Richard Shafritz Endowed Chair in Ophthalmology Research at the Children’s Hospital of Philadelphia.

**Role of the Funder/Sponsor:** The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**The Postnatal Growth and ROP (G-ROP) Study Group.** The G-ROP Study Group investigators include the following: Office of Study Chair: The Children’s Hospital of Philadelphia: Gil Binenbaum, MD, MSCE (Principal Investigator [PI]), Lauren A. Tomlinson, BS (Project Manager), Trang B. Duros, Anh Nguyen. Data Coordinating Center - University of Pennsylvania Perelman School of Medicine: Gui-shuang Ying, PhD (PI), Maureen G. Maguire, PhD, Mary Brightwell-Arnold, BA, SCP, James Shaffer, MS, Yinxi Yu, MS, Maria Blanco BS, Trina Brown BS, Christopher P. Helker, MSPH. Clinical Centers: Emory University School of Medicine (Children’s Healthcare of Atlanta): Amy Hutchinson, MD (PI), Carrie Young, RN. University of Colorado Denver (University of Colorado Hospital, Children’s Hospital Colorado): Emily McCourt, MD (PI), Anne Lynch, MD (Co-I), Jennifer Cathcart, MPH, Ashlee Cerda, MPH, Levi Bonnell, MPH, Tamara Thevarajah, MS. Albany Medical College: Gerard P. Barry, MD (PI), Marilyn Fisher, MD, MS (Co-I), Maria V. Battaglia, BS, MS, Alex M. Drach, BA, Kevin Hughes, BA. Lehigh Valley Hospital: Nachammai Chinnakaruppan, MD (PI), Andrew Meyer, MD (PI), Christina Gogal, BS, CCRC, Cynthia Beitler, BS, MT, BB (ASCP), CCRC, Lauri Centolanza, BS, MT (ASCP), Keith T. Moyer, MS, Mary Sobotor CLA-ASCP, CCRC. Johns Hopkins University (Johns Hopkins Hospital): Pamela Donohue, ScD (PI), Michael X. Repka, MD (Co-I), Jennifer A. Shepard, CRNP, Megan Doherty, NNP. University at Buffalo (Women & Children’s Hospital of Buffalo): James D. Reynolds, MD (PI), Erin Connelly. Medical University of South Carolina: Edward Cheeseman, MD, MBA (PI), Kinsey Shirer, RN, Carol Bradham, COA, CCRC, Allison McAlpine, Sudeep Sunthakar. University of Illinois at Chicago: Javaneh Abbasian, MD (PI), Janet Lim, MD. Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s Hospital Medical Center, Good Samaritan Hospital, and University of Cincinnati Medical Center): Michael Yang, MD (PI), Patricia Cobb, MS, Elizabeth L. Alfano. Nationwide Children’s Hospital (Nationwide Children’s Hospital, Riverside Methodist Hospital, Grant Medical Center, Doctors Hospital): David Rogers, MD (PI), Rachel E. Reem, MD, Amanda Schreckengost, MA, Rae R. Fellows, M.Ed., CCRC, Kaitlyn Loh, Madeline A. McGregor, Thabit Mustafa, Ivy Dean, Rachel Miller, Tess Russell, Rebecca Stattler, Sara Maletic, Theran Jake Selph. Kapi’olani Medical Center for Women and Children: David Young (PI), Andrea Siu, MPH, RAC, Michele Kanemori, George Kingston. University of Texas at Houston (Children’s Memorial Hermann Hospital): Megan Geloneck, MD (PI), Robert Feldman (PI), Ted Baker, Laura Baker, Ephrem Melese, MD. Indiana University (Riley Hospital for Children at Indiana University Health): Kathryn Haider, MD (PI), Jingyun Wang, PhD (PI), Elizabeth Hynes, RNC-NIC,



CLC. University of Iowa (University of Iowa Stead Family Children's Hospital): Edward F. Bell, MD (PI), Alina V. Dumitrescu, MD (Co-I), Jonathan M. Klein, MD (Co-I), Gretchen A. Cress, RN, MPH, Avanthi S. Ajjarapu, Kristine Berge, MSN, Eric Boeshart, Morgan Dorsey, Bethany M. Funk, Grace Hach, Claire L. Johnson, Kevin Kurian, Emily Miller, Angela C. Platt. Queen's University (Kingston Health Sciences Center): Christine Law, MD (PI), Andrew Gissing. Loma Linda University (Loma Linda University Children's Hospital): Leila Khazaeni, MD (PI), Jennifer Dunbar, MD (CoI), Kelley Hawkins, Sharon Lee, RN, Lily Sung, Carly Leggitt. University of Louisville (Norton Children's Hospital): Aparna Ramasubramanian, MD (PI), Rahul Bhola, MD (PI), Michelle Bottorff, COA, CCRC, Neviana Dimova, MD, MS, Rachel Keith, PhD, MSN, NP-C, Laura Thomas RN, BSN, CCRN. University of Minnesota (Masonic Children's Hospital, formerly University of Minnesota - Amplatz Children's Hospital): Jill Anderson, MD (PI), Raymond G. Areaux, Jr., MD (Co-I), Ann Marie Holleschau, BA, CCRP, Jordan Gross, Andrea Kramer. Vanderbilt Eye Institute and Vanderbilt University Medical Center: (Monroe Carell Jr. Children's Hospital at Vanderbilt): David Morrison, MD (PI), Sean Donahue, MD, PhD (Co-I), Carsyn Saige Wilkins, Neva Fukuda, CO, Sandy Owings, COA, CCRP, Scott Ruark. University of Oklahoma (The Children's Hospital at OU Medical Center / The University of Oklahoma Health Sciences Center): R. Michael Siatkowski, MD (PI), Faizah Bhatti, MD (Co-I), Vanessa Bergman, COT, CCRC, Karen Corff, APRN, NNP, Kari Harkey, RNC-NIC, Amy Manfredo, APRN-CNP, Ashley Helmbrecht, DNP, APRN-CNP, Shrenik Talsania, MBBS, MPH, CPH, Terri Whisenhunt, MS, RN. University of Nebraska (Nebraska Medicine): Donny Suh, MD, FAAP (PI), Ann Anderson Berry, MD, PhD (Co-I), Denise Lynes APRN-CNS, MSN, Kelly C. Erikson, MPH. The Children's Hospital of Philadelphia (The Children's Hospital of Philadelphia, Hospital of the University of Pennsylvania, Pennsylvania Hospital): Gil Binenbaum, MD, MSCE (PI), Soraya Abbasi, MD (PI), Haresh Kirpalani, MD, MSc, Graham E. Quinn MD, MSCE, Lindsay Dawson, MD, Lauren A. Tomlinson, BS. University of Pittsburgh (Children's Hospital of Pittsburgh, Magee Women Hospital of UPMC): Christin Sylvester, MD (PI), Kanwal Nischa, MD (PI), Lauren Runkel, MA. Rhode Island Hospital (Women and Infants Hospital of Rhode Island): Wendy S. Chen, MD, PhD (PI), Deidrya Jackson. Saint Louis University (Cardinal Glennon Children's Hospital): Bradley Davitt, MD (PI), Dawn Govreau, COT, Linda Breuer, LPN, September Noonan, RN. University of Utah (Primary Children's Hospital and University of Utah Hospital): Robert Hoffman, MD (PI), Joanna Beachy, MD, PhD, Kelliann Farnsworth, COT, Katie Jo Farnsworth, CRC, Deborah Harrison, MS, Ashlie Bernhisel, Bonnie Carlstrom. University of California San Francisco (UCSF Benioff Children's Hospital and Zuckerberg San Francisco General Hospital, formerly San Francisco General Hospital): Alejandra G. de Alba Campomanes, MD, MPH (PI), Yizhuo Bastea-Forte, Lucia Rivera Sanchez, Jacquelyn Kemmer, Alexandra Neiman, Sarah Sitati-Ng'Anda MD. Seattle Children's Hospital (Seattle Children's Hospital, University of Washington Medical Center): Kristina Tarczy-Hornoch, MD, D.Phil, (PI), Francine Baran, MD (PI), Lauren Eaton. The Hospital for Sick Children (Sick Kids), Toronto: Nasrin Najm-Tehrani, MB BCH, MSc, FRCS Ed (Ophth), FRCS (PI), Tanya Grossi, Maram Isaac, Robin Knighton. Los Angeles Biomedical Research Institute (Harbor-UCLA Medical Center): Monica Ralli Khitri, MD (PI), Madeline Del Signore, RN. Crozer-Chester Medical Center (Crozer Chester Medical Center, Delaware County Memorial Hospital): Cynthia Dembofsky, MD (PI), Andrew Meyer, MD (PI), Karen Flaherty, Tracey Harris, Jamie Heeneke, Nemours/Alfred I. duPont Hospital for Children: Dorothy Hendricks, MD (PI), Christopher M. Fecarotta, MD (PI), Alicia Oliviant Fisher, MS, Mark Paullin, MS. Cost-Effectiveness Component: Beth Israel Deaconess Medical Center: John Zupancic, MD, MS, ScD (PI). Executive/Editorial Committee: Alejandra de Alba Campomanes, MD MPH, Edward F. Bell, MD, Gil Binenbaum, MD, MSCE, Pamela Donohue, ScD, David Morrison, MD, Graham E. Quinn, MD, MSCE, Michael X. Repka, MD, David L. Rogers, MD, Lauren A. Tomlinson BS, Michael Yang, MD, Gui-shuang Ying, PhD.

**Disclaimer:** The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

## ABBREVIATIONS


<b>BW</b>	Birth weight
<b>CI</b>	Confidence interval
<b>CS</b>	Conventional screening
<b>GA</b>	Gestational age
<b>G-ROP</b>	Growth for Retinopathy of Prematurity Study
<b>ROP</b>	Retinopathy of prematurity
<b>PMA</b>	Post-menstrual age
<b>QALY</b>	Quality adjusted life years

<b>USD</b>	United States dollars
<b>WTP</b>	Willingness to pay


## LIST OF REFERENCES

1. Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol.* 2003;121(12):1684–94. [PubMed: 14662586]
2. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study. *Pediatrics.* 2005;116(1):15–23. [PubMed: 15995025]
3. Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. *Archives of Ophthalmology.* 2005;123:311–8. [PubMed: 15767472]
4. Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics.* 2018;142(6): e20183061
5. Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, Antigua J, et al. The CHOP postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. *Arch Ophthalmol.* 2012;130(12):1560–5. [PubMed: 23229697]
6. Binenbaum G, Ying GS, Tomlinson LA, Postnatal Growth and Retinopathy of Prematurity Study Group. Validation of the Children’s Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model. *JAMA Ophthalmol.* 2017;135(8):871–7. [PubMed: 28715553]
7. Cao JH, Wagner BD, Cerda A, McCourt EA, Palestine A, Enzenauer RW, et al. Colorado retinopathy of prematurity model: a multi-institutional validation study. *Journal of American Association for Pediatric Ophthalmology and Strabismus Journal of American Association for Pediatric Ophthalmology and Strabismus.* 2016;20(3):220–5. [PubMed: 27166790]
8. Eckert GU, Fortes Filho JB, Maia M, Procianoy RS. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. *Eye (Lond).* 2012;26(3):400–6. [PubMed: 22193874]
9. Lofqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LE, Ley D, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. *Arch Ophthalmol.* 2009;127(5):622–7. [PubMed: 19433710]
10. Wu C, Lofqvist C, Smith LE, VanderVeen DK, Hellstrom A, Consortium W. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. *Arch Ophthalmol.* 2012;130(8):992–9. [PubMed: 22491391]
11. Binenbaum G, Bell EF, Donohue P, Quinn G, Shaffer J, Tomlinson LA, et al. Development of modified screening criteria for retinopathy of prematurity: Primary results from the Postnatal Growth and Retinopathy of Prematurity Study. *JAMA Ophthalmol.* 2018;136(9):1034–40. [PubMed: 30003216]
12. Quinn GE, Ying GS, Bell EF, Donohue PK, Morrison D, Tomlinson LA, et al. Incidence and early course of retinopathy of prematurity: Secondary analysis of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. *JAMA Ophthalmol.* 2018;136(12):1383–9. [PubMed: 30326046]
13. Dawson L, De Alba Campomanes A, Zupancic J, Binenbaum G. Time and motion study for retinopathy of prematurity examinations [Abstract]. *Journal of American Association for Pediatric Ophthalmology and Strabismus.* 2016(20):e14.
14. Bureau of Labor Statistics US Department of Labor. Occupational Employment Statistics: U.S. Government Printing Office; [Available from: [https://www.bls.gov/oes/current/oes\\_nat.htm#29-0000](https://www.bls.gov/oes/current/oes_nat.htm#29-0000)].

15. Doximity. 2018 Physician Compensation Report 2018 [Available from: [https://s3.amazonaws.com/s3.doximity.com/careers/2018\\_physician\\_compensation\\_report.pdf](https://s3.amazonaws.com/s3.doximity.com/careers/2018_physician_compensation_report.pdf)].
16. Kamholz KL, Cole CH, Gray JE, Zupancic JA. Cost-effectiveness of early treatment for retinopathy of prematurity. *Pediatrics*. 2009;123(1):262–9. [PubMed: 19117891]
17. Bureau of Economic Analysis U.S. Department of Commerce. Price Indexes for Personal Consumption Expenditures by Function 2018 [Available from: <https://apps.bea.gov/iTable/>].
18. Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: A review of measures for health services research in the United States. *Health Serv Res*. 2018;53(1):175–96. [PubMed: 27873305]
19. United States Department of Health and Human Services (US DHHS) Centers for Disease Control and Prevention - National Center for Health Statistics (NCHS) Division of Vital Statistics. Natality Public-Use WONDER Online Database 2017 [Available from: <http://wonder.cdc.gov/natality-current.html>].
20. Drummond M, Sculpher M, Klaxton C, Stoddart GL, Torrance G. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press; 2015. 464 p.
21. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ*. 2001;10(8):779–87. [PubMed: 11747057]
22. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. *Archives of Ophthalmology*. 1990;108:1408–16. [PubMed: 2222274]
23. Dunbar JA, Hsu V, Christensen M, Black B, Williams P, Beauchamp G. Cost-utility analysis of screening and laser treatment of retinopathy of prematurity. *Journal of American Association for Pediatric Ophthalmology and Strabismus*. 2009;13(2):186–90. [PubMed: 19393519]
24. Jackson KM, Scott KE, Graff Zivin J, Bateman DA, Flynn JT, Keenan JD, et al. Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. *Arch Ophthalmol*. 2008;126(4):493–9. [PubMed: 18413518]
25. Rothschild MI, Russ R, Brennan KA, Williams CJ, Berrones D, Patel B, et al. The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States. *Am J Ophthalmol*. 2016;168:110–21. [PubMed: 27130372]
26. van den Akker-van Marle ME, van Sorge AJ, Schalij-Delfos NE. Cost and effects of risk factor guided screening strategies for retinopathy of prematurity for different treatment strategies. *Acta Ophthalmol*. 2015;93(8):706–12. [PubMed: 26149829]
27. Yanovitch TL, Siatkowski RM, McCaffree M, Corff KE. Retinopathy of prematurity in infants with birth weight > or= 1250 grams - incidence, severity, and screening guideline cost-analysis. *Journal of American Association for Pediatric Ophthalmology and Strabismus*. 2006;10(2):128–34. [PubMed: 16678747]
28. Quinn GE, Dobson V, Saigal S, Phelps DL, Hardy RJ, Tung B, et al. Health-related quality of life at age 10 years in very-low-birth-weight children with and without threshold retinopathy of prematurity. *Arch Ophthalmol*. 2004;122(11):1659–66. [PubMed: 15534127]
29. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment--United States, 2003. *MMWR Morb Mortal Wkly Rep*. 2004;53(3):57–9. [PubMed: 14749614]



**Figure 1.**  
Decision tree model for the base case (Discharge) analysis



**Figure 2.**

Differences in mean costs and effects between Conventional Screening and G-ROP screening cohorts for the base case (Discharge), cost per case of Type 1 ROP detected. Each point represents one run of the simulation model as described in the text. Ellipse represents 95% confidence bound for joint distribution of cost and effectiveness.

Table 1.

Estimates of population, efficacy and resource use

Input	Value	Type	Range or Parameter	Source
<i>Estimates of population, efficacy and resource use</i>				
Sensitivity				
G-ROP	100.0 %	Beta distribution	n=4590 r=4589	(11)
CS <sup>a</sup>	99.4 %	Beta distribution	n=459 r=456	(11)
Specificity				
G-ROP	32.3 %	Beta distribution	n=7024 r=2269	(11)
CS <sup>a</sup>	11.8. %	Beta distribution	n=6197 r=827	(11)
Gestational Age (weeks)	22–32	Empirical distribution <sup>a</sup>		(19)
Birth Weight by GA	400–5000	Empirical distribution <sup>a</sup>		(19)
ROP Incidence by GA	0 – 0.31	Probability table <sup>a</sup>		(11)
Time for Examination				
MD	14 (SD 7.7)	Normal distribution	mean=14 SD=7.7	Observation <sup>d</sup>
RN	15.2 (SD 7.9)	Normal distribution	mean=15.2 SD=7.9	Observation <sup>d</sup>
Coordinator	21.9 (SD 8.0)	Normal distribution	mean=21.9 SD=8.0	Observation <sup>d</sup>
Number of examinations				
With ROP	6.1 (SD 2.9)	Normal distribution	mean=6.1 SD=2.9	(11)
Without ROP	2.6 (SD 1.5)	Normal distribution	mean=2.6 SD=1.5	(11)
Probability of laser photocoagulation				
If Type 1 detected	1.0	Point estimate	NA	Assumption
If Type 1 missed	0	Point estimate	NA	Assumption
Probability of retinal surgery				
If Type 1 detected	0.064	Point estimate	NA	(2)
If Type 1 missed	0.43	Point estimate	NA	(22)
Discount rate	0.03	Point estimate	0.015 – 0.045	(20)
Utility				
Good visual outcome w/o ROP	0.97	Point estimate	NA	(28)

Input	Value	Type	Range or Parameter	Source
Poor visual outcome with ROP	0.27	Point estimate	0.14 – 0.41	(28)
Good visual outcome with ROP	0.87	Point estimate	0.44 – 1.00	(28)
Probability of poor visual outcome				
Without ROP	0	Point estimate	NA	Assumption
With ROP detected and treated	0.143	Point estimate	0.143 – 0.198	(2)
With ROP not detected or treated	0.643	Point estimate	NA	(3)
<i>Estimates of unit cost<sup>b</sup></i>				
Hourly personnel cost				
Ophthalmologist	254	Point estimate	127 – 381	(15)
RN	48	Point estimate	24 – 72	(14)
Coordinator	22	Point estimate	11 – 33	(14)
Retinal surgery	13,343	Point estimate	6,672 – 20,015	(16)
Laser photocoagulation	3,114	Point estimate	2,180 – 4,048	(16)
Lifetime cost of poor visual outcome	791,432	Point estimate	554,002 – 1,028,862	(29)

<sup>a</sup>Conventional Screening

<sup>b</sup>Full details in Supplemental Tables

<sup>c</sup>Values are in 2017 US dollars

<sup>d</sup>Observational study ancillary to current project (13); details in methods section above

**Table 2.**Details of Screening Performance through Discharge in United States Birth Cohort <sup>a b</sup>

<b>Parameter</b>	<b>Conventional Screening</b>	<b>G-ROP Screening</b>
Total Cost	\$ 30,885,069	\$ 27,953,089
Type 1 ROP detected	3,948	3,973
Type 1 ROP missed	26	1
Eligible for serial examination	68,331	54,258
Not eligible for serial examination	9,950	24,023
Number of examinations	189,220	152,987
No Type 1 ROP, Flagged by model	64,383	50,285
No Type 1 ROP, Not flagged	9,924	24,022

<sup>a</sup>Through 32 weeks gestational age, inclusive n = 78,281<sup>b</sup>Values rounded to 0 digits

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Table 3.**

Calculation of Point Estimate of Cost-effectiveness for Primary Outcome, Dollars per Case of Severe Visual Impairment Prevented Through Discharge<sup>a</sup>

Comparator	Cost (\$) C	Incremental Cost C	Effectiveness <sup>c</sup> E	Inc Effectiveness E	ICER <sup>d</sup> C/ E
G-ROP	27,953,089	-2,931,980	3,973	25	DOMINANT
CS	30,885,069		3,948		

<sup>a</sup>Values rounded to 0 digits

<sup>b</sup>Conventional Screening

<sup>c</sup>Cases of Type 1 ROP detected

<sup>d</sup>Incremental cost-effectiveness ratio

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript